about
Cisplatin ototoxicity and protection: clinical and experimental studiesSystems biology of cisplatin resistance: past, present and futureEffect of dicycloplatin, a novel platinum chemotherapeutical drug, on inhibiting cell growth and inducing cell apoptosisLiquid Chromatography Electrospray Ionization Tandem Mass Spectrometric (LC/ESI-MS/MS) Study for the Identification and Characterization of In Vivo Metabolites of Cisplatin in Rat Kidney Cancer Tissues: Online Hydrogen/Deuterium (H/D) Exchange StudyProtection of cisplatin cytotoxicity by an inactive cyclin-dependent kinase.Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy.The effect of tetrandrine combined with cisplatin on proliferation and apoptosis of A549/DDP cells and A549 cells.A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancerNanocarriers for delivery of platinum anticancer drugs.Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals.Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment.Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance.Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.Platinum drugs in the treatment of non-small-cell lung cancerCdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicityPicoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatinPanobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilizationDependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2Nitrooleic acid protects against cisplatin nephropathy: role of COX-2/mPGES-1/PGE2 cascade.On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapyNew-generation platinum drugs in the treatment of cisplatin-resistant cancers.Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment.Recurrent oral cancer: current and emerging therapeutic approaches.JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistanceAsperolide A, a marine-derived tetranorditerpenoid, induces G2/M arrest in human NCI-H460 lung carcinoma cells, is mediated by p53-p21 stabilization and modulated by Ras/Raf/MEK/ERK signaling pathway.A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cellsElevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1The liver X receptor agonist TO901317 protects mice against cisplatin-induced kidney injury.In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.Genetic variants of BCL2 gene predict clinical outcomes of non-small-cell lung cancer patients treated with platinum-based chemotherapy in a Chinese population.Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 inhibition.Wentilactone A as a novel potential antitumor agent induces apoptosis and G2/M arrest of human lung carcinoma cells, and is mediated by HRas-GTP accumulation to excessively activate the Ras/Raf/ERK/p53-p21 pathway.Benzyl isothiocyanate inhibits HNSCC cell migration and invasion, and sensitizes HNSCC cells to cisplatin.Nanocapsules of platinum anticancer drugs: development towards therapeutic use.Metal-organic frameworks as potential drug delivery systems.DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications.Research Progress in the Modification of Quercetin Leading to Anticancer Agents.The effect of potential supramolecular-bond promoters on the DNA-interacting abilities of copper-terpyridine compounds.
P2860
Q24628775-9548DF69-17DD-4994-A0F2-A48578E05AE9Q26863585-8024B1B8-B2DD-4B3F-BC03-312B3B5EA78CQ28485137-F28575F4-3C4F-4BDF-ACE6-23007F8D555FQ28547006-808BAA24-27AB-4DBE-BFFC-7E9A3159B2C6Q30495496-F692A935-286D-4BFB-BD26-4B8030D91E5EQ31123584-3ACE3815-E5EF-4837-B920-24994992A1BEQ32179390-775E835B-5C24-4B96-B524-1A3D8D95D73CQ34243429-367937FB-08EC-4460-9C99-2DFFBB9A0F7DQ34338695-5ADFA1B5-1661-42FF-8416-310E672A69F1Q34393336-15D2E727-A141-4230-ADDC-612042190B9AQ34517743-0FE0ABAD-935F-4FAD-84DB-95C445C9A22CQ34545482-1E1DFCAB-13A0-4423-9296-FF9A309EAB37Q34562736-D76A9FD8-CEAD-4637-BD63-F81BB7B699AAQ34914365-F8F9ADFB-5197-4F00-A32A-55947D479B26Q34954760-B18C5D49-9F53-4DB0-AB40-8BC8356D7F00Q34979646-266091DF-48A6-4C4A-A00E-E71DA6DE76F7Q35007734-ACFA1B77-DBF5-4B9B-977B-C4ADE6F5F1B0Q35059923-5A85E515-7031-4F50-AE7A-B347FA645F2FQ35220766-57C1EEE7-FE97-4883-99EC-CE5C2B562BE1Q35227002-5E1BBCB6-EE01-4869-ABA7-6F11C76F66C1Q36107216-063F7844-EA91-4CFD-86B4-6FEA74B9B193Q36210926-BA20DC2F-8CC8-472A-8988-3511E7132CA4Q36253687-1D6CF108-6C1A-489A-86E6-B2BE575A1923Q36283038-F74FB05C-0BBD-474D-8D5D-E94E62A24163Q36291991-190561FB-A140-421D-B4BD-482DE4673911Q36297939-89AB3B23-0CAF-4C0D-A00C-BFD4BB0C5BE9Q36806673-29FDA316-0D6B-4EB3-B631-0AEE98F5E2FEQ36852560-95A804BA-4A88-49B5-BD53-EEAE9121E88CQ36974153-7114AF7C-42EF-4CC1-A061-596889FDB70BQ37071339-B7FEE8C2-5A42-431D-B090-233DF4B0793FQ37352731-B8F0D27D-0825-4B3A-88D9-D209BA751AC3Q37382540-82678C28-87A0-415A-BF25-CA22F4C956FFQ37407348-94F4AD83-EA0D-4DC6-A92C-A7CCA77AA5DAQ37424084-80C0E675-BDEC-4A7F-8A81-C3232FF92AC3Q37619254-B89999D4-79E7-49C7-B534-ABBD92492327Q37855865-C9632BA1-E491-49B1-9F4B-6C846C089BB8Q38058895-27E83EDB-D605-4AAF-AFCD-EA86ABD7FEE4Q38121955-62976C98-B7C0-4FF3-9E3A-BCD1B62CBA60Q38652060-DE8EF676-82E8-49FB-B946-CD78C372F73FQ38842569-766FCB94-99C7-4308-B727-3C90CD5E7E0F
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinical perspectives on platinum resistance.
@ast
Clinical perspectives on platinum resistance.
@en
type
label
Clinical perspectives on platinum resistance.
@ast
Clinical perspectives on platinum resistance.
@en
prefLabel
Clinical perspectives on platinum resistance.
@ast
Clinical perspectives on platinum resistance.
@en
P1433
P1476
Clinical perspectives on platinum resistance.
@en
P2093
Giaccone G
P304
9-17; discussion 37-8
P356
10.2165/00003495-200059004-00002
P478
59 Suppl 4
P577
2000-01-01T00:00:00Z
P6179
1017978717